In Committee from the Senate of Canada - Social Affairs – April 26, 2012
Senior representatives from medical research and review groups testified as part of the committee's study on prescription pharmaceuticals in the country, with a focus on clinical trials.
Jack Corman from the Institutional Review Board Services organization spoke about the weaknesses in Canadian clinical trial procedures. Helen Stevenson from the Reformulary Group spoke about her company’s role in reviewing prescription drug costs. Dr. Mukul Sharma from the Canadian Stroke Consortium discussed his organization’s methods aimed at minimizing biases during trials and research projects.